Justin Zelin
Stock Analyst at BTIG
(0.99)
# 3,992
Out of 5,240 analysts
40
Total ratings
29.27%
Success rate
-12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Maintains: Buy | $6 → $9 | $8.15 | +10.43% | 2 | Jan 23, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $28.93 | +55.57% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $20.89 | +168.07% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $21.38 | +133.86% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.16 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.32 | +506.06% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $28.90 | +114.53% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.51 | +1,477.91% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $31.70 | +294.32% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $0.92 | +660.79% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $4.72 | +323.73% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $43.56 | -3.58% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.65 | +122,957.99% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $28.95 | +214.34% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $8.07 | +1,882.65% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.75 | +814.29% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $28.67 | +213.92% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $9.48 | +227.00% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $47.08 | -67.08% | 1 | Mar 28, 2023 |
ImmunityBio
Jan 23, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $8.15
Upside: +10.43%
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $28.93
Upside: +55.57%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $20.89
Upside: +168.07%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $21.38
Upside: +133.86%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.32
Upside: +506.06%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $28.90
Upside: +114.53%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.51
Upside: +1,477.91%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $31.70
Upside: +294.32%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $0.92
Upside: +660.79%
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $4.72
Upside: +323.73%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $43.56
Upside: -3.58%
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.65
Upside: +122,957.99%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $28.95
Upside: +214.34%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $8.07
Upside: +1,882.65%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $1.75
Upside: +814.29%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $28.67
Upside: +213.92%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $9.48
Upside: +227.00%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $47.08
Upside: -67.08%